Disruption of p53 in human cancer cells alters the responses to therapeutic agents.
Open accessThe DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.
Abstract
We have examined the effects of commonly used chemotherapeutic agents on human colon cancer cell lines in which the p53 pathway has been specifically disrupted by targeted homologous recombination. We found that p53 had profound effects on drug responses, and these effects varied dramatically depending on the drug. The p53-deficient cells were sensitized to the effects of DNA-damaging agents as a result of the failure to induce expression of the cyclin-dependent kinase inhibitor p21. In contrast, p53 disruption rendered cells strikingly resistant to the effects of the antimetabolite 5-fluorouracil (5-FU), the mainstay of adjuvant therapy for colorectal cancer. The effects on 5-FU sensitivity were observed both in vitro and in vivo, were independent of p21, and appeared to be the result of perturbations in RNA, rather than DNA, metabolism. These results have significant implications for future efforts to maximize therapeutic efficacy in patients with defined genetic alterations.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Some conventional chemotherapeutic drugs depend on the activation of p53 for their efficacy.”
From CDK4 inhibition diminishes p53 activation by MDM2 antagonists (2018) · cites this paper as [44]
The cited source says what the claim attributes to it.
In the citing paper
“Comparing p53-proficient and -deficient HCT116 cells, such a dependency was found in particular for 5-fluorouracil (5-FU)44.”
From CDK4 inhibition diminishes p53 activation by MDM2 antagonists (2018) · cites this paper as [44]
In the citing paper
“A series of clinical studies have confirmed that CRC patients with wild-type P53 can benefit from 5-FU, and CRC patients with mutant P53 have a poor prognosis when receiving adjuvant chemotherapy [258,259,260].”
From Drug Resistance in Colorectal Cancer: From Mechanism to Clinic (2022) · cites this paper as [259]
In the citing paper
“A series of clinical studies have confirmed that CRC patients with wild-type P53 can benefit from 5-FU, and CRC patients with mutant P53 have a poor prognosis when receiving adjuvant chemotherapy [258,259,260].”
From Drug Resistance in Colorectal Cancer: From Mechanism to Clinic (2022) · cites this paper as [259]
In the citing paper
“On the other hand, the same report showed that p53-deficient cells displayed a higher sensitivity towards topoisomerase inhibitors such as Adriamycin.”
From CDK4 inhibition diminishes p53 activation by MDM2 antagonists (2018) · cites this paper as [44]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Green, D. R., & Reed, J. C. (1998) · Science · doi:10.1126/science.281.5381.1309 · Cited by 8,965
p53, the cellular gatekeeper for growth and division
Levine, A. J. (1997) · Cell · doi:10.1016/s0092-8674(00)81871-1 · Cited by 7,693
Requirement for p53 and p21 to Sustain G 2 Arrest After DNA Damage
Bunz, F., Dutriaux, A., Lengauer, C., Waldman, T., Zhou, S., Brown, J. P., Sedivy, J. M., Kinzler, K. W., & Vogelstein, B. (1998) · Science · doi:10.1126/science.282.5393.1497 · Cited by 2,803 · cited 4×
“We attribute this difference to the small amount of p53independent p21 induction following DNA damage that occurs after adriamycin treatment of p53-deficient cells (not shown), similar to that observed after γ-irradiation (14).”
BackgroundMethodInfluentialSelf-citationA model for p53-induced apoptosis
Polyak, K., Xia, Y., Zweier, J. L., Kinzler, K. W., & Vogelstein, B. (1997) · Nature · doi:10.1038/38525 · Cited by 2,500
Self-citationKo, L. J., & Prives, C. (1996) · Genes & Development · doi:10.1101/gad.10.9.1054 · Cited by 2,344 · cited 1×
“Introduction The p53 gene is inactivated in the majority of human cancers, resulting in profound effects on cell birth and death processes (1, 2).”
BackgroundMice Lacking p21CIP1/WAF1 undergo normal development, but are defective in G1 checkpoint control
Deng, C., Zhang, P., Wade Harper, J., Elledge, S. J., & Leder, P. (1995) · Cell · doi:10.1016/0092-8674(95)90039-x · Cited by 2,113
p53 Status and the Efficacy of Cancer Therapy in Vivo
Lowe, S. W., Bodis, S., McClatchey, A., Remington, L., Ruley, H. E., Fisher, D. E., Housman, D. E., & Jacks, T. (1994) · Science · doi:10.1126/science.7973635 · Cited by 1,469 · cited 1×
“with mouse cells, for example, have provided unequivocal evidence of drug resistance after p53 inactivation (9, 10), but the extrapolation of these results to humans is far from straightforward.”
BackgroundApoptosis in cancer therapy: Crossing the threshold
Fisher, D. E. (1994) · Cell · doi:10.1016/0092-8674(94)90518-5 · Cited by 1,315
Is a p53-Regulated Inhibitor of G2/M Progression
Hermeking, H., Lengauer, C., Polyak, K., He, T.-C., Zhang, L., Thiagalingam, S., Kinzler, K. W., & Vogelstein, B. (1997) · Molecular Cell · doi:10.1016/s1097-2765(00)80002-7 · Cited by 1,251 · cited 1×
“The checkpoint function of p53 is mediated by the genes it transcriptionally regulates, including p21 (14, 15, 16) and 14-3-3σ (28), and keeps cells from progressing from G1 to S or G2 to M after DNA damage.”
BackgroundSelf-citationRadiation-induced cell cycle arrest compromised by p21 deficiency
Brugarolas, J., Chandrasekaran, C., Gordon, J. I., Beach, D., Jacks, T., & Hannon, G. J. (1995) · Nature · doi:10.1038/377552a0 · Cited by 1,242
Research works printed but not linked: 6
- Hawkins, 1996, Cancer Res, 56, 892
- O’Connor, 1997, Cancer Res, 57, 4285
- Waldman, 1995, Cancer Res, 55, 5187
- Geoffroy, 1994, Oncol Res, 6, 581
- Wyllie, 1997, Eur J Cell Biol, 73, 189
- Cory, 1979, Cancer Res, 39, 4905
Cited by
Items 801–900 of 1,000
Richartz, N., Duthil, E., Ford, A. M., Naderi, E. H., Bhagwat, S., Gilljam, K. M., Burman, M. M., Ruud, E., Blomhoff, H. K., & Skah, S. (2019) · Blood Advances · doi:10.1182/bloodadvances.2019000473 · Cited by 11
“The gene product of TP53 is regarded as an important barrier against cancer development,(4) as well as being imperative for successful cancer treatment.(5,6) The tumor suppressor p53 is a key factor in DNA damage responses, and it exerts most of its effect as a transcription factor.”
BackgroundHarakeh, S., Diab‐Assaf, M., Abu-El-Ardat, K., Niedzwiecki, A., & Rath, M. (2006) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2006.09.005 · Cited by 11
Bioluminescence Detection of Cells Having Stabilized p53 in Response to a Genotoxic Event
Rehemtulla, A., Taneja, N., & Ross, B. D. (2004) · Molecular Imaging · doi:10.1162/15353500200403175 · Cited by 11
“Recent work from the Vogelstein group emphasizes the need for methods to study p53 activation in vivo in response to therapeutic interventions [21].”
BackgroundCunningham, S. C., Gallmeier, E., Hucl, T., Dezentjé, D. A., Abdelmohsen, K., Gorospe, M., & Kern, S. E. (2006) · Cell Cycle · doi:10.4161/cc.5.10.2805 · Cited by 11
Analysis of p53–RNA interactions in cultured human cells
Riley, K. J.-L., & Maher, L. J. (2007) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2007.08.181 · Cited by 13
“Tested cell lines do (MCF-7, HCT116 +/+) or do not (PC-3, HCT116 −/−) express p53 [23].”
BackgroundMethodHepG2 cells recovered from apoptosis show altered drug responses and invasiveness
Wang, S., Xie, X., Wong, C. S. T., Choi, P. Y., & Fung, M. C. (2014) · Hepatobiliary & pancreatic diseases international · doi:10.1016/s1499-3872(14)60042-4 · Cited by 11
Molecular markers in colorectal cancer: genetic bases for a customised treatment
Casado, E., de Castro, J., Belda-Iniesta, C., Cejas, P., Feliú, J., Sereno, M., & González-Barón, M. (2007) · Clinical & Translational Oncology · doi:10.1007/s12094-007-0102-8 · Cited by 11
“[32, 33].”
Lopez‐Crapez, E., Bazin, H., Chevalier, J., Trinquet, E., Grenier, J., & Mathis, G. (2005) · Human Mutation · doi:10.1002/humu.20162 · Cited by 11
“Somatic mutations such as those found in the p53 gene influence both clinical outcome and response to therapy [Bunz et al., 1999].”
BackgroundRajić, Z., Butula, I., Zorc, B., Pavelić, S. K., Hock, K., Pavelić, K., Naesens, L. M. J., Clercq, E. D., Balzarini, J. M., Przyborowska, M., et al. (2009) · Chemical Biology & Drug Design · doi:10.1111/j.1747-0285.2009.00774.x · Cited by 11
“Even though two major tumor suppressor pathways p53 and p105 are not functional in HeLa cells, the ability of a cell to undergo apoptosis is not necessarily lost as there are other pathways that induce apoptosis (39).”
BackgroundIchikawa, W., Ooyama, A., Toda, E., Sugimoto, Y., Oka, T., Takahashi, T., Shimizu, M., Sasaki, Y., & Hirayama, R. (2006) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-006-0217-6 · Cited by 15
“In vitro studies have reported that loss of p53 function reduced cellular sensitivity of 5-FU [3, 16].”
BackgroundTumor response to radiotherapy is dependent on genotype-associated mechanisms in vitro and in vivo
Williams, J. R., Zhang, Y., Zhou, H., Gridley, D. S., Koch, C. J., Dicello, J. F., Slater, J. M., & Little, J. B. (2010) · Radiation Oncology · doi:10.1186/1748-717x-5-71 · Cited by 11
“We and others have used direct comparison of kinetics of regrowth delay between pairs of tumor types or between pairs of radiotherapy protocols [1,18] and while this method has significant statistical power in such a pair-wise comparison, it is limited in comparing response of multiple tumors that vary widely when irr…”
BackgroundMethodSelf-citationResistance to cytotoxic agents
Robert, J. (2001) · Current Opinion in Pharmacology · doi:10.1016/s1471-4892(01)00061-3 · Cited by 12
Exploring and Exploiting Instability
da Costa, L. T., & Lengauer, C. (2002) · Cancer Biology & Therapy · doi:10.4161/cbt.71 · Cited by 16
Self-citationCan Photodynamic Therapy Be an Alternative Method in Melanoma Treatment?
Choromańska, A., Kulbacka, J., Chwikowska, A., Skoucka, N., Gamian, A., & Saczko, J. (2011) · InTech eBooks · doi:10.5772/20168 · Cited by 10
Ağardan, N. B. M., & Torchilin, V. P. (2016) · Elsevier eBooks · doi:10.1016/b978-0-323-41532-3.00001-4 · Cited by 14
Nedara, K., Reinhardt, C., Lebraud, E., Arena, G., Gracia, C., Buard, V., Pioche‐Durieu, C., Castelli, F. A., Colsch, B., Bénit, P., et al. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.958155 · Cited by 11
“Among p53 target genes upregulated as a consequence of TRIAP1 loss, we observed the presence of its prototypical target p21, a cyclin-dependent kinase inhibitor known to play a crucial role in p53-mediated, stress-induced, cell growth inhibition (34, 56, 57).”
BackgroundDimitrijević, J. D., Solovjova, N., Bukonjić, A. M., Tomović, D. L., Milinkovic, M., Caković, A. Z., Bogojeski, J., Ratković, Z., Janjić, G. V., Rakić, A. A., et al. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241512504 · Cited by 10
“The p53 protein participates in the regulation of the cell cycle, DNA repair mechanisms, and apoptosis; which of these processes is the result of p53 activation, depends on the cell type and microenvironment [70].”
BackgroundA Fatty Acid Synthase Inhibitor Shows New Anticancer Mechanisms
Bueno, M. J., & Colomer, R. (2015) · EBioMedicine · doi:10.1016/j.ebiom.2015.08.023 · Cited by 10
Longley, D. B., & Johnston, P. G. (2007) · Humana Press eBooks · doi:10.1007/978-1-59745-200-7_11 · Cited by 11
Shin, S. Y., Ahn, S., Koh, D., & Lim, Y. (2016) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2016.09.067 · Cited by 10
Carlsson, M. J. L., Hu, G., & Ronne, H. (2018) · PLoS ONE · doi:10.1371/journal.pone.0196840 · Cited by 10
Decker, R. H., Levin, J., Kramer, L. B., Dai, Y., & Grant, S. (2003) · Biochemical Pharmacology · doi:10.1016/s0006-2952(03)00149-7 · Cited by 10
“Similarly, doxorubicin-mediated cell death was enhanced in colon carcinoma cells lacking p53, while 5-fluorouracil (5-FU) sensitivity was diminished markedly [6].”
BackgroundAnnor, G. K., Elshabassy, N., Lundine, D., Conde, D.-G., Xiao, G., Ellison, V., & Bargonetti, J. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.772315 · Cited by 10
“org) and the HCT116 colon cancer cell line that is p53−/− was a gift from Bert Vogelstein and were made as described (Bunz et al., 1998; Bunz et al., 1999).”
MethodStructural and dynamics insights into the GBA variants associated with Parkinson’s disease
Mahmood, A., Samad, A., Bano, S., Umair, M., Ajmal, A., Ilyas, I., Shah, A. A., Li, P., & Hu, J. (2023) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2023.2233617 · Cited by 9
“As mentioned before, it is critical to understand which variant respond to therapeutic agents (Bunz et al., 1999).”
BackgroundNovel compounds in the treatment of lung cancer: current and developing therapeutic agents
Bao, R., & Chan (2011) · Journal of Experimental Pharmacology · doi:10.2147/jep.s7804 · Cited by 12
“The most extensively tested gene therapy is the replacement of the p53 gene which is mutated in 40% to 70% of NSCLC samples and which is associated with resistance to chemotherapy and radiotherapy.(125) Phase I studies of p53 replacement with various viral vectors injected directly or delivered by bronchoalveolar lava…”
Wohak, L. E., Baranski, A.-C., Krais, A. M., Schmeiser, H. H., Phillips, D. H., & Arlt, V. M. (2018) · Mutagenesis · doi:10.1093/mutage/gey025 · Cited by 9
Zhao, L., Santiago, A., Liu, J., & Liao, D. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m610749200 · Cited by 10
Mutations in the P53 Tumor Suppressor Gene in Colorectal Cancer in Taiwan
Chang, F.-H., Tzeng, D., Lung, F., Lee, T., Chen, T., & Hsu, L. (2003) · The Kaohsiung Journal of Medical Sciences · doi:10.1016/s1607-551x(09)70464-4 · Cited by 9
Induction of apoptosis in oral squamous carcinoma cells by pyrrolo-1,5-benzoxazepines
O’Callaghan, K., Palagano, E., Butini, S., Campiani, G., Williams, D. C., Zisterer, D. M., & O’Sullivan, J. (2015) · Molecular Medicine Reports · doi:10.3892/mmr.2015.3832 · Cited by 10
Targeting Apoptosis as a Therapeutic Approach in Cancer
Abd-Elhamid, R., Nazmy, M., & Fathy, M. (2020) · Minia Journal of Medical Research · doi:10.21608/mjmr.2022.221093 · Cited by 9
The Intrinsic Pathway of Apoptosis
Kaufmann, S. H. (2007) · Humana Press eBooks · doi:10.1007/978-1-59745-221-2_1 · Cited by 14
de Anta, J. M., Perez-Castro, A., Freire, R., & Mayol, X. (2006) · Anti-Cancer Drugs · doi:10.1097/01.cad.0000236311.73703.d2 · Cited by 12
Beliën, A., Schepper, S. D., Floren, W., Janssens, B., Mariën, A., King, P., Dun, J. V., Andries, L. J., Voeten, J., Bijnens, L., et al. (2006) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-06-0112 · Cited by 9
“A well-known example is the tumor suppressor p53, which controls cellular response to radiation and chemotherapeutic agents and is inactivated in the majority of human tumors (2, 3).”
BackgroundPilati, P., D, S. M. M., Rossi, C. R., Scalerta, R., Alaggio, R., Giacomelli, L., Geroni, C., Nitti, D., & Lise, M. (2003) · World Journal of Surgery · doi:10.1007/s00268-003-6804-3 · Cited by 9
“Other investigators maintain that the poor sensitivity correlates with the overexpression of multi-drug resistance genes [5] or with the deregulation of cell cycle/apoptosis-related genes [6, 7].”
BackgroundMdm2 Plays a Positive Role as an Effector of p53-Dependent Responses
Giono, L. E., & Manfredi, J. J. (2007) · Cell Cycle · doi:10.4161/cc.6.17.4647 · Cited by 10
Predictive Markers for Colorectal Cancer: Current Status and Future Prospects
Longley, D. B., McDermott, U., & Johnston, P. G. (2003) · Clinical Colorectal Cancer · doi:10.3816/ccc.2003.n.003 · Cited by 9
Satou, M., Aizawa, S., Hayakari, M., Ookawa, K., & Tsuchida, S. (2003) · Cancer Science · doi:10.1111/j.1349-7006.2003.tb01434.x · Cited by 9
Thymidylate synthase inhibition triggers glucose‐dependent apoptosis in p53‐negative leukemic cells
Muñoz‐Pinedo, C., Robledo, G., & López‐Rivas, A. (2004) · FEBS Letters · doi:10.1016/j.febslet.2004.06.044 · Cited by 10
Molavand, M., Majidinia, M., & Yousefi, B. (2025) · IUBMB Life · doi:10.1002/iub.70074 · Cited by 10
“Although p53 deficiency leads to the induction of resistance to 5-FU, studies on 5- FU-resistant p53 +/+ CRC cells revealed elevated levels of Bcl-2 and Bcl-xL, alongside reduced levels of Bax [97, 98].”
Molecular determinants of the response of cancer cells towards geldanamycin and its derivatives
Seo, E., Khelifi, D., Fayez, S., Feineis, D., Bringmann, G., Efferth, T., & Dawood, M. (2023) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2023.110677 · Cited by 9
Diakité, B., Kassogué, Y., Dolo, G., Kassogué, O., Keita, M. L., Joyce, B. T., Neuschler, E. I., Wang, J., Musa, J., Traore, C. B., et al. (2020) · BMC Medical Genetics · doi:10.1186/s12881-020-01072-4 · Cited by 8
Almuzaini, N. A., Moore, M., Robert-Guroff, M., & Thomas, M. A. (2022) · Microbiology Spectrum · doi:10.1128/spectrum.01881-21 · Cited by 9
“is commonly found in human cancer (70, 71).”
BackgroundValdés, G., & Iwamoto, K. S. (2013) · International Journal of Radiation Biology · doi:10.3109/09553002.2013.797620 · Cited by 8
“Th e loss of p53 function has been shown to reduce cellular sensitivity to 5-FU in vitro (Bunz et al. 1999, Longley et al. 2002).”
BackgroundThe Life Cycle of P53: A Key Target in Drug Development
Finlan, L. E., & Hupp, T. R. (2006) · Springer eBooks · doi:10.1007/0-387-23695-3_7 · Cited by 8
Pritchard, D. M., Bower, L., Potten, C. S., Jackman, A. L., & Hickman, J. A. (2000) · PubMed · Cited by 8
Drug resistance in prostate cancer cell lines is influenced by androgen dependence and p53 status
Serafin, A. M., Akudugu, J., & Böhm, L. (2002) · Urological Research · doi:10.1007/s00240-002-0277-y · Cited by 8
“The finding of superior drug sensitivity in p53-defective prostate cell lines is in contrast to results on human colon cancer cell lines which have shown that p53 disruption rendered cells resistant to the antimetabolite, 5-fluorouracil [6].”
BackgroundResultChang, P. M., Chen, P., Chu, P., Wang, L.-W., Tai, S., Tsai, T.-L., Huang, J.-L., Wang, Y.-F., Chang, S., & Yang, M. (2008) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-008-0702-1 · Cited by 8
Vikhanskaya, F., & Broggini, M. (2002) · International review of cytology · doi:10.1016/s0074-7696(02)19013-9 · Cited by 8
Failure of Pancreatic Cancer Chemotherapy: Consequences of Drug Resistance Mechanisms
Bhardwaj, V., Murthy, S. M., James, C. K., & Bhush, A. (2012) · InTech eBooks · doi:10.5772/27122 · Cited by 7
Epirubicin permeation of personal protective equipment can induce apoptosis in keratinocytes
Pieri, M. C., Quagliuolo, L., Porta, R. L., Silvestre, A., Miraglia, N., Pedata, P., Acampora, A., Castiglia, L., Sannolo, N., & Boccellino, M. (2012) · Journal of Exposure Science & Environmental Epidemiology · doi:10.1038/jes.2012.38 · Cited by 7
Allen, W. L., Turkington, R. C., Stevenson, L. S., Carson, G., Coyle, V. M., Hector, S., Dunne, P. D., Schaeybroeck, S. V., Longley, D. B., & Johnston, P. G. (2012) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-12-0207 · Cited by 9
Molecular Determinants of Intrinsic Multidrug Resistance in Cancer Cells and Tumors
Monti, E. (2007) · Humana Press eBooks · doi:10.1007/978-1-59745-035-5_14 · Cited by 7
“However, some notable exceptions (71) indicate that p53 status is not a universal predictor of treatment response, in part because not all drugs absolutely require p53 for their apoptosis-inducing effects (51).”
BackgroundBahar, A., Whitby, P., Holley, S. L., Hoban, P. R., Elder, J. B., Deakin, M., Hall, C., Clayton, R. N., Williams, G. T., & Farrell, W. E. (2006) · Genes Chromosomes and Cancer · doi:10.1002/gcc.20401 · Cited by 7
“…HCT116 cells engineered for TP53 deficiency are resistant to 5FU mediated apoptosis (Bunz et al., 1999), we first compared the response of SW480 cells, that harbor mutant TP53 (Rochette et al., 2005), to that seen in wild type HCT116 cells that are sensitive to this challenge (Bunz et al., 1999).”
BackgroundResultInfluentialCytoplasmic Localization of Cyclin Kinase Inhibitor p21 Delays the Progression of Apoptosis.
Arai, D., Nomura, N., Fukuchi, K., & Gomi, K. (2006) · PubMed · Cited by 7
Raza, A., & Ghosh, S. S. (2019) · Biochemistry Insights · doi:10.1177/1178626418818182 · Cited by 7
“Multiple strategies, involving the amalgamation of 5-FU with other chemotherapeutic drugs, anti-tumour proteins, radiation therapy, or with cytokines, are implored to enhance the sensitivity of the cancer cells towards 5-FU [11-13].”
BackgroundFas/FasL expression in tumor biopsies: a prognostic response factor to fluoropyrimidines?*
Bézulier, K., Fina, F., Roussel, M., Bun-Llopet, S.-S., Ciccolini, J., Martin, P., Milano, G. A., Aubert, C., & Barra, Y. (2003) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1046/j.0269-4727.2003.00510.x · Cited by 7
No anti-apoptotic effects of single copies of mutant p53 genes in drug-treated tumor cells
Fritzsche, C., Zeller, G. C., Knaup, K. X., & Roemer, K. (2004) · Anti-Cancer Drugs · doi:10.1097/01.cad.0000136878.96680.f5 · Cited by 8
Influence of p53 and bcl-2 on chemosensitivity in benign and malignant prostatic cell lines
Serafin, A. M., & Böhm, L. (2005) · Urologic Oncology Seminars and Original Investigations · doi:10.1016/j.urolonc.2004.11.007 · Cited by 7
Cancer colorectal : altérations moléculaires pronostiques
Boige, V., Malka, D., Taïeb, J., Pignon, J., & Ducreux, M. P. (2004) · Gastroentérologie Clinique et Biologique · doi:10.1016/s0399-8320(04)94836-1 · Cited by 8
“Une hypothèse alternative serait que, plutôt qu’une chimiosensibilité supérieure des CCR MSI+, les CCR MSI- seraient plus chimiorésistants du fait d’altérations plus fréquentes des gènes suppresseurs de tumeur, notamment TP53, dont le rôle dans la réponse aux anticancéreux, dont le FU, est essentiel [49].”
BackgroundCosgrove, D., Park, B. H., & Vogelstein, B. (2017) · Wiley eBooks · doi:10.1002/9781119000822.hfcm005 · Cited by 8
Self-citationLee, R., Ellison, V., Forbes, D., Gao, C., Katanov, D., Kern, A., Levine, F. A., Leybengrub, P., Ogunwobi, O. O., Xiao, G., et al. (2024) · Cancers · doi:10.3390/cancers16244194 · Cited by 8
“The HCT116 TP53 knockout cells were from a well characterized colorectal cancer line generously given to us by Bert Vogelstein [15].”
Luo, F., Li, J., Liu, J., & Liu, K. (2022) · Cancer Gene Therapy · doi:10.1038/s41417-022-00493-y · Cited by 6
Significance of a calcium-binding protein S100A14 expression in colon cancer progression
Hashida, H., & Coffey, R. J. (2022) · Journal of Gastrointestinal Oncology · doi:10.21037/jgo-21-528 · Cited by 6
“DKO-1, HCT-8, SW480, SW620, HCT116, HT-29 (colorectal cancer cell line), HCT-15, DLD-1, Caco-2, and HCA-7 cells were obtained from the American Type Culture Collection (Manassas, VA, USA) (23).”
Sadowska, A. J., Sawicka, D., Godlewska, K., Guzińska-Ustymowicz, K., Zapora, E., Sokołowska, E., & Car, H. (2023) · Molecules · doi:10.3390/molecules28031352 · Cited by 6
Blagosklonny, M. V., & Darżynkiewicz, Z. (2006) · Springer eBooks · doi:10.1007/0-387-23695-3_17 · Cited by 6
p14ARFinduces apoptosisviaan entirely caspase-3-dependent mitochondrial amplification loop
Milojkovic, A., Hemmati, P., Müer, A., Overkamp, T., Chumduri, C., Jänicke, R. U., Gillissen, B. F., & Daniel, P. T. (2013) · International Journal of Cancer · doi:10.1002/ijc.28279 · Cited by 7
Identification of two novel functional p53 responsive elements in the herpes simplex virus-1 genome
Hsieh, J., Kuta, R., Armour, C. R., & Boehmer, P. E. (2014) · Virology · doi:10.1016/j.virol.2014.04.019 · Cited by 7
“In the presence of 5-fluorouracil (5-FU), a DNA damaging agent and p53 co-activator (Bunz et al., 1999), reporter gene activity was enhanced in all cases, with p53RE-S mediating higher activity than p53RE-L as observed in the absence of 5-FU.”
Aljada, A., Saleh, A., & Mousa, S. A. (2013) · Journal of Cancer Science & Therapy · doi:10.4172/1948-5956.1000204 · Cited by 6
“Key mechanisms for the development of drug resistance include: 1) activation of antistress frontline defense such as over-expression of drug efflux pumps P-glycoprotein and MRP [2-4], drug inactivating enzymes cytochrome P450 and GST-pi [5], and anti-oxidant molecules SOD and catalase [6,7], 2) activation of repair an…”
BackgroundYerba Mate (Ilex ParaguariensisSt. Hilaire) Saponins Inhibit Human Colon Cancer Cell Proliferation
Puangpraphant, S., Berhow, M. A., & de Mejı́a, E. G. (2012) · ACS symposium series · doi:10.1021/bk-2012-1109.ch018 · Cited by 6
Xia, Y.-X., Lam, C. S., Li, W., Sarwar, M. S., Liu, K., Lee, K. M., Zhang, H., & Tsang, S. W. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20081917 · Cited by 6
“In accordance with other studies, p21 induction can be modulated via p53-dependent or p53-independent mechanisms in rapidly proliferating cancer cells [7,25].”
BackgroundByczek-Wyrostek, A., Zawisza-Puchałka, J., Gruca, A., Papaj, K., Grynkiewicz, G., Rusin, M., Szeja, W., & Rusin, A. (2013) · Journal of Chemistry · doi:10.1155/2013/191563 · Cited by 6
“HCT 116 −/− p53 (both p53 alleles deleted by targeted homologous recombination) [22] were a gift from Dr.”
AbdelAzizS.A., A., MohamedA., F., ZahkoukS.A., M., & AliR.A., M. (2017) · International Journal of Advanced Research · doi:10.21474/ijar01/3376 · Cited by 6
Lehmann‐Che, J., Turpin, E., Bertheau, P., Espié, M., & de Thé, H. (2007) · médecine/sciences · doi:10.1051/medsci/200723111021 · Cited by 6
Zimmermann, S., Biniossek, M. L., Maurer, C., Münzer, P., Pantić, M., Veelken, H., & Martens, U. M. (2009) · PROTEOMICS · doi:10.1002/pmic.200900232 · Cited by 7
“Yet the original work on the here presented HCT-116 cell line variants describe the dependence of DNA damage responses on p21 [42] and p53 [43] proceeded in studies about the requirement of the p21 expression by a p53dependent mechanism to fully develop senescence properties after DNA damage [44].”
BackgroundJaiswal, A. S., & Narayan, S. (2004) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-004-0591-6 · Cited by 6
“…of the p53/p21 (Waf-1/Cip-1) pathway The availability of the HCT-116(p53+/+) and HCT116(p53)/)) cell lines that express the wild-type p53 protein and nullizygous, respectively, provided the opportunity to assess the role of p53 in ceramide-induced effects on colon cancer cells (Bunz et al. 1999).”
BackgroundMethodInfluentialRusso, P., Ottoboni, C., Malacarne, D., Crippa, A., Riou, J., & O’Connor, P. M. (2002) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.300.1.220 · Cited by 6
“The effects on 5-FU sensitivity were observed both in vitro and in vivo, were independent of p21, and appeared to be the result of alterations in RNA, rather than DNA, metabolism (Bunz et al., 1999).”
BackgroundResultInfluentialZihlif, M., Hameduh, T., Bulatova, N., & Hammad, H. M. (2023) · Biomedical Reports · doi:10.3892/br.2023.1670 · Cited by 6
“CDKN1A gene, upregulated in both hypoxia models, is a major inhibitor of p53‑dependent apoptosis (67); expression of this gene protects cells from doxorubicin‑induced apoptosis (68).”
BackgroundGene expression alterations in hypoxic A549 lung cancer cell line
Abualnadi, R., Tarboush, N. A., Shhab, M. A. A., & Zihlif, M. A. (2024) · Biomedical Reports · doi:10.3892/br.2024.1871 · Cited by 5
“In mammary epithelial cells, overexpression of c‑Fos has been shown to promote the development of a drug resistant phenotype resulting in cell polarity loss and EMT, which promotes invasive and metastatic growth (26).”
BackgroundInfluentialXu, H., Zhang, X., Kang, L., Feng, S., Li, Y., & Zhao, G. (2025) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2025.140143 · Cited by 6
Wang, X., Xi, M., Lu, X., & Tan, X. (2025) · Pharmaceuticals · doi:10.3390/ph18030317 · Cited by 6
Gomez, A. V., & Ingelman‐Sundberg, M. (2008) · Expert Review of Clinical Pharmacology · doi:10.1586/17512433.2.1.55 · Cited by 5
Determine the Effect of p53 on Chemosensitivity
Senturk, E., & Manfredi, J. J. (2012) · Methods in molecular biology · doi:10.1007/978-1-62703-236-0_9 · Cited by 5
Genetic determinants for activated fluoropyrimidine chemotherapy
Gmeiner, W. H. (2006) · Drug Development Research · doi:10.1002/ddr.20090 · Cited by 5
“Mutations in the p53 gene are among the most frequent in cancer and the p53 status of cancer cells has been shown to affect patient response to FPs and other anticancer drugs, particularly those that damage DNA as a principal cytotoxic mechanism [Bunz et al., 1999].”
BackgroundAhn, M., Choi, J.-H., Oh, H.-S., Lee, Y.-Y., Kim, I.-S., Choi, I.-Y., Lee, K.-H., Song, K.-W., & Park, C.-K. (2005) · Cancer Research and Treatment · doi:10.4143/crt.2005.37.4.216 · Cited by 5
Hypoxia inhibition of camptothecin-induced apoptosis by Bax loss
Park, K., Abdela, W., Fermin, C. D., Reddy, G., Habtemariam, T., Chung, J. W., Park, M., Seol, D., & Kim, M. (2012) · Biologia · doi:10.2478/s11756-012-0037-6 · Cited by 6
Bach, S. P., Williamson, S. E., O’Dwyer, S., Potten, C. S., & Watson, A. J. M. (2006) · British Journal of Cancer · doi:10.1038/sj.bjc.6603224 · Cited by 6
“Similar effects have been reported in this model following radiation treatment (Merritt et al, 1994) and in a colorectal cancer cell line subject to 5-FU (Bunz et al, 1999).”
BackgroundResultCorrection: The Akt Inhibitor ISC-4 Synergizes with Cetuximab in 5-FU-Resistant Colon Cancer
Allen, J. E., Gallant, J., Dicker, D. T., Amin, S., Irby, R., Sharma, A. K., & El‐Deiry, W. S. (2013) · PLoS ONE · doi:10.1371/annotation/aaa12360-0c90-42c3-bc43-d00022b68b81 · Cited by 5
Huang, Z., Luo, S., Wang, Z., Zhang, Z., Jiang, B., Nie, Q. H., & Zhang, J. (2026) · eLife · doi:10.7554/elife.100623 · Cited by 10
“This damage triggers apoptosis, a process of programmed cell death, thus inhibiting the growth and proliferation of malignant cells ( Kuipers et al., 2015 ; Bunz et al., 1999 ; Chang et al., 2014 ).”
Bae, Y., Seo, J. H., & Jeong, W. (2024) · Phytomedicine Plus · doi:10.1016/j.phyplu.2024.100641 · Cited by 4
Epigenetic Regulation of G6PD Drives Metabolic Reprogramming in Intrahepatic Cholangiocarcinoma
Nakano, Y., Tanaka, M., Sakamoto, T., Hashimoto, M., Tobo, T., Saito, H., Abe, T., Ikehara, T., Ofuchi, T., Kawata, K., et al. (2025) · Cancer Science · doi:10.1111/cas.70202 · Cited by 4
Lundine, D., Annor, G. K., Chavez, V. A., Maimos, S., Syed, Z., Jiang, S., Ellison, V., & Bargonetti, J. (2022) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-22-0133 · Cited by 4
“Human breast cancer cell line MDA-MB-468 (RRID:CVCL_0419) was purchased from ATCC (www.atcc.org) and the HCT116 (RRID: CVCL_S744) colon cancer cell line that is p53 / was a gift from Bert Vogelstein (33, 34).”
BackgroundTokuyama, S., Kato, H., Takahashi, H., Ueda, K., Arita, A., Ueda, R., Seto, H., Sekido, Y., Hata, T., Hamabe, A., et al. (2024) · Carcinogenesis · doi:10.1093/carcin/bgae040 · Cited by 4
Waldman, T. A. (2016) · Cancer Research · doi:10.1158/0008-5472.can-16-1972 · Cited by 4
Self-citationOmega-3 Fatty Acids in Cancer: Insight into the Mechanism of Actions in Preclinical Cancer Models
Joshi, A., Hegde, M. V., & Adekar, S. P. (2016) · Springer eBooks · doi:10.1007/978-3-319-40458-5_12 · Cited by 4
Puspita, N. A., & Alhebshi, H. (2019) · INDONESIAN JOURNAL OF PHARMACY · doi:10.14499/indonesianjpharm30iss4pp241 · Cited by 4
Role of the RNA-Binding Protein HuR in Apoptosis and Apoptosome Function
Kuwano, Y., Gallouzi, I., & Gorospe, M. (2009) · Springer eBooks · doi:10.1007/978-90-481-3415-1_10 · Cited by 5
“Through its growth inhibitory influence, p21 has emerged as a critical component of the cellular anti-apoptotic program (Gorospe and Holbrook 1996; Waldman et al. 1996; Gorospe et al. 1996; 1997; Bunz et al. 1998, 1999; Marches et al. 1999): likewise, p21 has been proposed to be an important component of the HuR-elici…”
BackgroundTumour site, sex, and survival in colorectal cancer
Rosell, R., & Abad, A. (2000) · The Lancet · doi:10.1016/s0140-6736(05)73438-3 · Cited by 4
Apoptosis, senescence and cancer (cancer drug discovery and development)
Young, A. R. J. (2009) · British Journal of Cancer · doi:10.1038/sj.bjc.6604944 · Cited by 4
Robust p53 phenotypes and prospective downstream targets in telomerase-immortalized human cells
Miciak, J. J., Petrova, L., Sajwan, R., Pandya, A., Deckard, M., Munoz, A. J., & Bunz, F. (2025) · Oncotarget · doi:10.18632/oncotarget.28690 · Cited by 5
Self-citationErmine, K., Chen, D., Hao, S., Liu, Z., Lu, X., Leibowitz, B. J., Wang, P., Jin, Z., Schoen, R. E., Yu, J., et al. (2025) · Cancer Letters · doi:10.1016/j.canlet.2025.218169 · Cited by 4
Metadata
- Authors
- Bunz, F., Hwang, P. M., Torrance, C., Waldman, T., Zhang, Y., Dillehay, L., Williams, J., Lengauer, C., Kinzler, K. W., & Vogelstein, B.
- Affiliations
- Howard Hughes Medical Institute (US)
- Georgetown University (US)
- Johns Hopkins University (US)
- Corresponding author
- Vogelstein, Bert
- Venue
- Journal of Clinical Investigation
- Published
- 1999-08-01
- Volume
- 104
- Issue
- 3
- Pages
- 263-269
- ISSN
- 0021-9738 (ISSN-L)
- PMC
- PMC408422
- OpenAlex
- W1982097971
- Cited by
- 1,044
- References
- 33
- Citations by year
- 2026: 10 · 2025: 14 · 2024: 17 · 2023: 26 · 2022: 23 · 2021: 19 · 2020: 27 · 2019: 26 · 2018: 25 · 2017: 24 · 2016: 36 · 2015: 32 · 2014: 35 · 2013: 43 · 2012: 38
- FWCI
- 22.48
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Journal of Clinical Investigation (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Foundation for Cancer Research
- Johns Hopkins University
- National Institutes of Health
- National Cancer Institute (CA 57345, R01CA057345, P50CA062924, R37CA057345, CA 62924)
- Topics
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Health Sciences › Medicine › Pathology and Forensic Medicine › Genetic factors in colorectal cancer
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › PI3K/AKT/mTOR signaling in cancer
- Keywords
- p53, p53 deficiency, chemoresistance, 5-fluorouracil, antimetabolite resistance, p21, cyclin-dependent kinase inhibitors, DNA-damaging agents, chemosensitization, colon cancer, colorectal cancer, RNA metabolism, drug response
- MeSH terms
- Animals, Antineoplastic Agents, Colonic Neoplasms, DNA Damage, Doxorubicin, Fluorouracil, Humans, Mice, Nude, Neoplasm Transplantation, Transplantation, Heterologous, Tumor Cells, Cultured, Genes, p53, Tumor Suppressor Protein p53, Cyclins, Apoptosis, Gene Deletion, Drug Resistance, Neoplasm, Cyclin-Dependent Kinase Inhibitor p21, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.